Community stories and news

  • ProQR Update August 2022

    Community news

    Announced today (August 11, 2022), ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).

    RNA illustration
  • Building an Inclusive ProQR

    Community news

    At ProQR we strive to create an inclusive culture where everyone is valued for who they are and individual differences and contributions are recognized and appreciated. Therefore, we decided for this Pride Month June 2022, to visually demonstrate our support and acknowledgment of the LGBTQ+ community by changing our logo to incorporate the pride rainbow flag.

    Rainbow image with text We Wish You A Happy Pride Month!
  • ProQR update and additional sepofarsen Illuminate trial analyses

    Community news

    ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.

    ProQR logo on the left. The word update on the right.
  • Rare Disease Day 2022

    Community news

    On behalf of all ProQRians, happy Rare Disease Day 2022. Both within ProQR and outside, we join the community in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, and supporters.

    28 February 2022 is Rare Disease Day. Rare disease day logo on the top right. Portrait of Maartje living with Usher syndrome on the right. #RareDiseaseDay www.rarediseaseday.org
  • Rare Disease Day 2021

    Community news

    Even in lockdown we have been working hard as ProQRians to stay connected to the inherited retinal disease community. Rare Disease Day is a unique awareness day due to its global reach and significance.

    A collage of four ProQRians on a purple background. From left to right: Daniel de Boer, Eleni Skandalaki, Andy Bolan and Marko Potman. At the top left is the logo of Rare Disease Day
  • Always excited about RNA therapies

    Community news

    He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.

    A photo of Gerard Platenburg
  • Still going strong / One challenge after another

    Community news

    There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.

    A photo of Hee Lam Chan
  • “A new way of designing medicines”

    Community news

    The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of designing medicines for genetic diseases that were previously ‘out of reach’ for existing technologies.”

    A photo of Bart Klein
  • “Top-notch science that leads to a treatment”

    Community news

    2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. The work of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 (LCA10) patients, has progressed steadily. The team is expecting to start a first clinical trial in patients this year.

    A photo of Patricia Biasutto